Figure 1.
Cutaneous lesions in SLE patients.
The skin injury of SLE presents multiple morphologies, including atrophic scaly purplish-red macules, papules and plaques, indurate erythema and vacuities as well.
Figure 2.
Deposit of immunoreactants along epidermal-dermal junction in lesional skin.
Skin sections were incubated with fluorescein isothiocyanate (FITC)-conjugated anti-human IgG, IgA, IgM, and C3 antibodies and visualized with a fluorescence microscope. A and B indicates the staining patterns of single immunoreactant detected from individual biopsy. The representative staining of the coexistence of two and three immunoreactants from two biopsies were shown in C and D, respectively. N.C, negative control without adding FITC-conjugated antibody.
Table 1.
Patterns of immunoreactants in the lesional skin of patients with SLE.
Table 2.
Association of cutaneous IgM with serological disorders and SLEDAI.
Figure 3.
The comparison of serum C3 concentration and SLEDAI in groups of patients Patients were first divided into DIF− and DIF+ groups.
DIF+ group was then divided into two subgroups according to the existence pattern (A, B) and the number of immunoreactants(C, D), respectively. Serum C3(A, C) and SLEDAI(B,D) were compared among each of four groups. Each symbol represents one individual, and the bar indicates the mean. Statistical analysis was performed with one-way analysis of variance followed by Dunn’s post hoc test for three groups. *P<0.05, ** P<0.01.
Table 3.
Association of the number of cutaneous immunoreactants with serological disorders and SLEDAI.